{"nctId":"NCT01365052","briefTitle":"Safety Trial of Naproxen Sodium/ Diphenhydramine","startDateStruct":{"date":"2011-05"},"conditions":["Pain"],"count":326,"armGroups":[{"label":"Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)","type":"EXPERIMENTAL","interventionNames":["Drug: Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy, ambulatory, male and female volunteers ages 12 and older\n* History of experiencing occasional sleeplessness accompanied by aches and pains at least two times, but not continually for more than 14 days per month, in at least 2 of the past 3 months\n* Female subjects of childbearing potential must be using a medically acceptable form of birth control, e.g., oral or patch contraceptives, intrauterine device, Depo-ProveraÂ®, for at least 1 month prior to screening (3 months on oral contraceptives), or double-barrier and have a negative pregnancy test at Screening. Female subjects of nonchildbearing potential must be amenorrheic for at least 2 years or have had a hysterectomy and/or bilateral oophorectomy\n* Be willing and able to participate in all scheduled visits, treatment plan, tests and other trial procedures according to the protocol\n* Provide a personally signed and dated informed consent indicating that the subject has been informed of all pertinent aspects of the trial, (subjects \\<18 years of age must sign a written assent and have parental or guardian consent).\n\nExclusion Criteria:\n\n* History of hypersensitivity to naproxen sodium, acetaminophen, or any NSAIDs (Nonsteroidal Antiinflammatory Drugs), diphenhydramine or any other antihistamines, and similar pharmacological agents or components of the product\n* Evidence or history of clinically significant (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or malignancies with the last 5 years\n* A history of a chronic or severe sleep problem which does not respond to OTC (Over-the-counter) medication and/or requires a prescription hypnotic or sedative\n* Currently experiencing chronic pain or on chronic NSAID therapy (defined as taking a daily \\[5 to 7 days per week\\] regimen of prescription or OTC NSAIDs)\n* Current or past history of gastrointestinal ulcers or bleeding or other bleeding disorders\n* Use of any OTC or prescription medications with which the administration of naproxen, acetaminophen, or any NSAIDs, diphenhydramine or any other antihistamines or sedatives, is contraindicated\n* Chronic use of other products containing diphenhydramine, including topical products\n* Use of steroids or blood thinning (anticoagulant) drugs (aspirin 81 mg is permitted if the dose has been taken for at least one month prior to screening)","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Subjects Who Discontinued Due to an Adverse Event for Those Subjects Who Are Randomized and Take at Least One Dose of Investigational Product","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With Any Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product","description":"Please see further details in Adverse Events (AE) section","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.6","spread":null},{"groupId":"OG001","value":"45.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With Any Serious Adverse Event for Those Subjects Who Were Randomized and Took at Least One Dose of Investigational Product","description":"Please see further details in AE section","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Treatment Compliance - Number of Capsules Taken","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.1","spread":"1.73"},{"groupId":"OG001","value":"19.9","spread":"2.98"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Treatment Compliance - Duration of Exposure to Treatment in Days","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":"0.76"},{"groupId":"OG001","value":"9.8","spread":"1.37"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":217},"commonTop":["HEADACHE","SOMNOLENCE","BACK PAIN","NAUSEA","DIARRHOEA"]}}}